Safety profile of prophylactic intracameral moxifloxacin in cataract surgery

Irfan Aslam Khattak¹, Adnan Aslam Saleem², Amer Shahzad¹

ABSTRACT

Purpose: To determine the safety of intracameral moxifloxacin with regards to endothelial toxicity

Methods: In this case control study, 490 patients (equally divided into two groups) were treated with intracameral moxifloxacin (250 micrograms/0.050 ml) or an equal volume of balanced salt solution at the conclusion of cataract surgery. Safety parameters, including endothelial cell counts and corneal pachymetry, were evaluated preoperatively and 1 week postoperatively.

Results: All patient’s completed one week follow-up. No significant difference (p-value = 0.089) was seen in the decrease in endothelial cell count (ECC) between the two groups. Similarly no significant difference (p-value > 0.094) in central corneal thickness (CCT) was found between the two groups.

Conclusion: A single injection of 0.05 ml intracameral moxifloxacin (250 microgram) given at the close of cataract surgery is safe for corneal health in regards to endothelial cell count and central corneal thickness. Al-Shifa Journal of Ophthalmology 2015; 11(2): 90-97. © Al-Shifa Trust Eye Hospital, Rawalpindi, Pakistan.